PSMA PET Use in Oncology: From Diagnosis to Implications for Different Treatment Options
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 5
Special Issue Editor
Interests: radiation therapy; combination therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue explores the expanding role of PSMA PET imaging in the management of prostate cancer, from its diagnostic value to its impact on treatment decision-making. As PSMA-targeted PET technologies continue to advance, they offer unprecedented accuracy in detecting primary tumors, assessing disease extent, and identifying metastatic spread. These capabilities are reshaping clinical pathways and enabling more personalized therapeutic strategies. By bridging imaging findings with treatment choices, PSMA PET influences surgical planning, radiotherapy targeting, systemic therapy selection, and the development of novel radioligand treatments. This Special Issue welcomes original research, reviews, and clinical perspectives that examine how PSMA PET informs patient care, improves outcomes, and shapes the future of prostate cancer treatment.
Dr. Fernando Munoz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PSMA PET
- prostate cancer
- molecular imaging
- treatment decision making
- precision oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
